1 Clinical Neuroendocrinology, Max Planck Institute of Psychiatry , Munich, Germany .
J Neurotrauma. 2014 Jan 1;31(1):99-107. doi: 10.1089/neu.2013.3002. Epub 2013 Dec 11.
We performed a screening on patients with traumatic brain injury (TBI) or subarachnoid hemorrhage (SAH) to determine the prevalence of post-traumatic hypopituitarism in neurorehabilitation in a cross-sectional, observational single-center study. In addition, the therapeutic consequences of our screening were analyzed retrospectively. From February 2006 to August 2009, patients between 18 and 65 years (n=509) with the diagnosis of TBI (n=340) or SAH (n=169) were screened within two weeks of admittance to neurorehabilitation as clinical routine. Blood was drawn to determine fasting cortisol, free thyroxine (fT4), prolactin, testosterone or estradiol, and insulin-like growth factor I (IGF-I). Patients with abnormalities in the screening or clinical signs of hypopituitarism received further stimulation tests: growth hormone releasing hormone -L-arginine-test and adrenocorticotrophic hormone (ACTH)-test (n=36); ACTH-test alone (n=26); or insulin tolerance test (n=56). In our screening of 509 patients, 28.5% showed lowered values in at least one hormone of the hypothalamus-pituitary axis and 4.5% in two or more axes. The most common disturbance was a decrease of testosterone in 40.7% of all men (in the following 13/131 men were given substitution therapy). Low fT4 was detected in 5.9% (n=3 were given substitution therapy). Low IGF-I was detected in 5.8%, low cortisol in 1.4%, and low prolactin in 0.2%; none were given substitution therapy. Further stimulation tests revealed growth hormone deficiency in 20.7% (n=19/92) and hypocortisolism in 23.7% (n=28/118). Laboratory values possibly indicating hypopituitarism (33%) were common but did not always implicate post-traumatic hypopituitarism. Laboratory values possibly indicating hypopituitarism were common in our screening but most patients were clinically not diagnosed as pituitary insufficient and did not receive hormone replacement therapy. A routine screening of all patients in neurorehabilitation without considering the time since injury, the severity of illness and therapeutic consequences seems not useful.
我们对创伤性脑损伤(TBI)或蛛网膜下腔出血(SAH)患者进行了筛查,以在一项横断面、观察性单中心研究中确定神经康复中创伤后垂体功能减退症的患病率。此外,还回顾性分析了我们筛查的治疗后果。
从 2006 年 2 月至 2009 年 8 月,在神经康复入院后两周内,作为临床常规,对 509 名年龄在 18 至 65 岁之间的患者(TBI 患者 340 名,SAH 患者 169 名)进行了筛查。采集血液以测定空腹皮质醇、游离甲状腺素(fT4)、催乳素、睾酮或雌二醇和胰岛素样生长因子 I(IGF-I)。在筛查中发现异常或有垂体功能减退临床体征的患者接受了进一步的刺激试验:生长激素释放激素-L-精氨酸试验和促肾上腺皮质激素(ACTH)试验(n=36);仅进行 ACTH 试验(n=26);或胰岛素耐量试验(n=56)。
在我们对 509 名患者的筛查中,28.5%的患者至少有一种下丘脑-垂体轴激素值降低,4.5%的患者有两种或两种以上轴激素值降低。最常见的异常是所有男性中 40.7%的睾酮降低(以下 13/131 名男性给予了替代治疗)。5.9%(n=3)的患者发现游离甲状腺素降低,5.8%的患者发现 IGF-I 降低,1.4%的患者发现皮质醇降低,0.2%的患者发现催乳素降低;均未给予替代治疗。进一步的刺激试验显示生长激素缺乏症 20.7%(n=19/92),皮质醇不足 23.7%(n=28/118)。实验室值可能提示垂体功能减退症(33%)很常见,但并不总是意味着创伤后垂体功能减退症。在我们的筛查中,实验室值可能提示垂体功能减退症很常见,但大多数患者在临床上并未被诊断为垂体功能不足,也未接受激素替代治疗。对于神经康复中的所有患者,不考虑受伤时间、疾病严重程度和治疗后果,进行常规筛查似乎没有用处。